Latest news
LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:11:01 GMTLisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash - Quiver QuantitativeQuiver Quantitative · Tue, 04 Aug 2026 11:15:00 GMTTNL Mediagene Establishes Special Committee to Evaluate Strategic Alternatives, Engages Imperial Capital as Financial Advisor to Pursue Strategic Alternatives to Maximize Shareholder Value - newsfilecorp.comnewsfilecorp.com · Mon, 03 Aug 2026 12:00:00 GMTOnfolio Pursues Strategic Alternatives to Reshape Portfolio and Drive Shareholder Value - finance.yahoo.comfinance.yahoo.com · Tue, 28 Jul 2026 07:00:00 GMT